{"id":46660,"date":"2025-07-07T18:46:19","date_gmt":"2025-07-07T18:46:19","guid":{"rendered":"https:\/\/www.europesays.com\/us\/46660\/"},"modified":"2025-07-07T18:46:19","modified_gmt":"2025-07-07T18:46:19","slug":"u-s-gastric-cancer-diagnostics-market-size-share-and-growth-report-2034","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/46660\/","title":{"rendered":"U.S. Gastric Cancer Diagnostics Market Size, Share and Growth Report 2034"},"content":{"rendered":"

<\/p>\n

The U.S.
\ngastric cancer diagnostics market size<\/b><\/a> is expected to be worth around 970.95
\nmillion by 2034, increasing from USD 524.15 million in 2025, representing a
\nhealthy CAGR of 7.09% from 2025 to 2034.<\/p>\n

<\/p>\n

The U.S. gastric cancer diagnostics market
\nis growing due to several factors such as increasing awareness, improved
\ndiagnostic techniques, and a rise in risk factors. Increasing cases of gastric
\ncancer due to the huge adoption of a westernized lifestyle, which includes the
\ningestion of processed
\nfood<\/b><\/a>, fatty meals, huge sugar, and red meat. U.S. increase in metabolic
\nchallenging factors, like high body mass index (BMI) or growing bone mineral
\ndensity, and rate of consumption of alcohol, which lead to gastric dysfunction
\nin the U.S. Gastric cancer is diagnosed through various methods such as upper
\nendoscopy, biopsy<\/b><\/a>,
\nimaging tests, blood tests, and tumour markers.<\/p>\n

The Complete Study is Now Available for
\nImmediate Access | Download the Sample Pages of this Report@ <\/b>https:\/\/www.novaoneadvisor.com\/report\/sample\/9170<\/b><\/a>
\n<\/b><\/p>\n

U.S. Gastric Cancer Diagnostics Market
\nHighlights:<\/b><\/p>\n

\u2b25\ufe0eBy product, the reagents and consumables segment dominated the
\nmarket with the largest share in 2024.<\/p>\n

\u2b25\ufe0eBy product, the instruments segment is expected to show the fastest
\ngrowth over the forecast period.<\/p>\n

\u2b25\ufe0eBy disease type, the adenocarcinoma segment held the largest market
\nshare in 2024.<\/p>\n

\u2b25\ufe0eBy disease type, the gastric lymphoma segment is expected to show
\nsignificant growth in the market during the forecast period.<\/p>\n

\u2b25\ufe0eBy end-use, the hospitals segment generated the highest market
\nrevenue in 2024. <\/p>\n

\u2b25\ufe0eBy end-use, the diagnostic laboratories segment is expected
\nregister the fastest CAGR over the forecast period.<\/p>\n

Market Overview and Industry Potential<\/b><\/p>\n

The U.S. gastric cancer diagnostics market
\nis expanding rapidly due to a growing in GC rates in young adults in the U.S.,
\npredominantly due to a rise in the rate of NCGC, and the growth of the older
\npopulation ages 65 and older. The American Cancer Society’s estimates for
\ngastric cancer in the United States for 2025 are about 30,300 recent cases of
\nthis cancer (17,720 in men and 12,580 in women). About 10,780 deaths from this
\ntype of cancer (6,400 men and 4,380 women), which drives the market growth.<\/p>\n

Recent advancements in diagnostics
\ntechnologies like endoscopic ultrasound with fine-needle biopsy, narrow-band
\nimaging, magnification endoscopy, and artificial
\nintelligence<\/b><\/a>-enhanced methods are renovating gastric cancer detection,
\nstaging, and treatment. Endoscopic methods such as submucosal dissection and
\nmucosal resection are enhancing results for premalignant and malignant lesions.
\nThese development plays a significant role in endoscopy in lowering morbidity,
\nmortality, and healthcare expenses related to GI cancers.<\/p>\n

\u2b25\ufe0eFor Instance, In March 2025, Royal Philips<\/b><\/a>, a global leader
\nin health technology, announced the expansion of its partnership with Ibex
\nMedical Analytics (Ibex) and a novel release of Philips IntelliSite Pathology
\nSolution (PIPS) to further accelerate the adoption of AI-enabled digital
\npathology to address the pressure pathologists face because of the global
\nshortage of pathologists and the growing number of cancer patients.<\/p>\n

Buy Now Full Report:<\/b> https:\/\/www.novaoneadvisor.com\/report\/checkout\/9170<\/b><\/a><\/p>\n

Types of biomarkers for gastrointestinal
\ncancer<\/b><\/p>\n\n\n

Type of Biomarker<\/b><\/p>\n<\/td>\n\n

Example<\/b><\/p>\n<\/td>\n\n

Gastrointestinal Tumour Type<\/b><\/p>\n<\/td>\n<\/tr>\n\n\n

Histologic Staging<\/p>\n<\/td>\n\n

Dysplasia and cancer staging<\/p>\n<\/td>\n\n

All gastrointestinal cancers<\/p>\n<\/td>\n<\/tr>\n\n\n

Genetic and Family Risk<\/p>\n<\/td>\n\n

FAP testing<\/p>\n<\/td>\n\n

Colorectal cancer <\/p>\n<\/td>\n<\/tr>\n\n\n

Susceptibility<\/p>\n<\/td>\n\n

\u00a0Multi cytokine Polymorphism<\/p>\n<\/td>\n\n

Gastric<\/p>\n<\/td>\n<\/tr>\n\n\n

Diagnostic<\/p>\n<\/td>\n\n

Carino-embryonic antigen<\/p>\n<\/td>\n\n

Colorectal cancer CRC<\/p>\n<\/td>\n<\/tr>\n\n\n

Prognostic<\/p>\n<\/td>\n\n

P53, p16, beta-catenin<\/p>\n<\/td>\n\n

Oesophageal adenocarcinoma<\/p>\n<\/td>\n<\/tr>\n\n\n

Predictive<\/p>\n<\/td>\n\n

Erb32 for trastuzumab therapy, EGFR for gefitinib therapy<\/p>\n<\/td>\n\n

Gastric<\/p>\n<\/td>\n<\/tr>\n\n\n

Exposure<\/p>\n<\/td>\n\n

Nitrites\/DNA adducts<\/p>\n<\/td>\n\n

Oesophageal adenocarcinoma <\/p>\n<\/td>\n<\/tr>\n

What are Latest Trends in U.S. Gastric
\nCancer Diagnostics Market?<\/b><\/p>\n

\u2b25\ufe0eIn January 2025, Eisai
\nand Merck & Co., Inc<\/b><\/a>., Rahway, NJ, USA announced results from the
\nPhase 3 LEAP-015 trial evaluating LENVIMA (lenvatinib), the orally available
\nmultiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, plus
\nKEYTRUDA (pembrolizumab), the anti-PD-1 therapy from Merck & Co., Inc.,
\nRahway, NJ, USA, in combination with chemotherapy (LENVIMA plus KEYTRUDA-based
\nregimen), for the first-line treatment of patients with locally advanced
\nunresectable or metastatic human epidermal growth factor receptor 2
\n(HER2)-negative gastroesophageal adenocarcinoma.<\/p>\n

\u2b25\ufe0eIn March 2025, the Gastric
\nCancer Foundation<\/b><\/a> (GCF) announced the opportunity for its 2025 grant
\nprogram. The foundation will award $200,000 in seed funding to U.S.-based
\nresearchers focused on discovering early detection diagnostics and developing
\ninnovative therapies for the treatment of gastric cancer. GCF is presently
\naccepting letters of intent from interested researchers.<\/p>\n

\u2b25\ufe0eIn January 2025, Amgen announced that the U.S. Food and Drug
\nAdministration (FDA) had approved LUMAKRAS in combination with Vectibix for the
\ntreatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer
\n(mCRC), as determined by an FDA-approved test, who have received prior
\nfluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.<\/p>\n

Increasing Adoption of Automation in DNA
\nManufacturing: Market\u2019s Largest Potential<\/b><\/p>\n

Increasing research and development of
\nnovel biomarkers<\/b><\/a>
\nof gastric cancer, molecular biomarkers with predictive and prognostic
\nimplications, to improve understanding of the wide heterogeneity of gastric
\ncancer and progress effective targeted therapies to treat this cancer. There
\nare some predictive biomarkers like HER2 overexpression, HER2\/neu
\namplification, MSI-H, and PD-L1+ advantageous in gastric cancer, and an
\nincreasing number of clinical trials based on these biomarkers have
\ndemonstrated the effectiveness of targeted therapies alone or in combination
\nwith conventional chemotherapy. These biomarkers for GC are a hopeful area of
\nresearch that potentially enhances diagnostic accuracy and patient outcomes.<\/p>\n

U.S. Gastric Cancer Diagnostics Market
\nReport Scope<\/b><\/p>\n\n\n

Report Attribute<\/b><\/p>\n<\/td>\n\n

Details<\/b><\/p>\n<\/td>\n<\/tr>\n\n\n

Market size value in 2025<\/p>\n<\/td>\n\n

USD 524.15 Million<\/p>\n<\/td>\n<\/tr>\n\n\n

Revenue forecast in 2034<\/p>\n<\/td>\n\n

USD 970.95 Million<\/p>\n<\/td>\n<\/tr>\n\n\n

Growth rate<\/p>\n<\/td>\n\n

CAGR of 7.09% from 2025 to 2034<\/p>\n<\/td>\n<\/tr>\n\n\n

Actual data<\/p>\n<\/td>\n\n

2021 – 2024<\/p>\n<\/td>\n<\/tr>\n\n\n

Forecast period<\/p>\n<\/td>\n\n

2025 – 2034<\/p>\n<\/td>\n<\/tr>\n\n\n

Quantitative units<\/p>\n<\/td>\n\n

Revenue in USD million\/billion and CAGR
\n from 2025 to 2034<\/p>\n<\/td>\n<\/tr>\n\n\n

Report coverage<\/p>\n<\/td>\n\n

Revenue forecast, company ranking,
\n competitive landscape, growth factors, and trends<\/p>\n<\/td>\n<\/tr>\n\n\n

Segments covered<\/p>\n<\/td>\n\n

Product, Disease Type, End-use<\/p>\n<\/td>\n<\/tr>\n\n\n

Country scope<\/p>\n<\/td>\n\n

U.S.<\/p>\n<\/td>\n<\/tr>\n\n\n

Key companies profiled<\/p>\n<\/td>\n\n

Illumina, Inc.; Guardant Health, Natera,
\n Inc; Thermo Fisher Scientific; QIAGEN; Freenome Holdings Inc; Exact Sciences
\n Corporation; PathAI, Inc; GE Healthcare<\/p>\n<\/td>\n<\/tr>\n\n\n

Customization scope<\/p>\n<\/td>\n\n

Exact Sciences Corporation, Freenome
\n Holdings Inc., GE Healthcare, Guardant Health, Illumina, Inc, Natera,
\n Inc,PathAI, Inc, QIAGEN, Thermo Fisher Scientific<\/p>\n<\/td>\n<\/tr>\n

U.S. Gastric Cancer Diagnostics Market
\nSegmentation Analysis:<\/b><\/p>\n

By Product Analysis:<\/b><\/p>\n

The reagents and consumables segment
\ndominates in the U.S. gastric cancer diagnostics market, as a broad type of
\nreagents and consumables available, they are reliable, affordable solutions
\ndelivered with exceptional service and integrity. Diagnostic reagents and
\nconsumables for gastric cancer are significant in detecting the presence of
\ncancer cells and identifying the stage and location of the disease. Common
\ndiagnostic consumables are Imaging Tests, X-rays, Computed
\nTomography<\/b><\/a> (CT) Scan, Magnetic
\nResonance Imaging<\/b><\/a> (MRI), and Ultrasound, which are used in GC
\ndiagnostic.<\/p>\n

On the other hand, the instruments segment
\nis expected to grow significantly during the forecast period as Instruments
\nused in cancer diagnostics provide many advantages, such as earlier and more
\nprecise detection, enhanced treatment planning, and advanced patient results.
\nGeneral instruments include chemotherapy chairs, chemotherapy infusion pumps,
\nchemotherapy syringe pumps, chemotherapy infusion sets, implantable ports, and
\nvial adapters.<\/p>\n

By Disease Analysis:<\/b><\/p>\n

The adenocarcinoma segment dominates the
\nU.S. gastric cancer diagnostics market, as it is the most common form of
\ngastric cancer. It causes digestive issues and abdominal pain and stems from
\ngenetic, lifestyle, and dietary factors, while its treatment ranges from
\nsurgery to immunotherapy. Adenocarcinomas account for 90% to 95% trusted Source
\nof gastric cancers. These stomach cancers grow in some mutated gland cells that
\nare present in the mucosa, or the innermost lining of the stomach.<\/p>\n

The gastric lymphoma segment is expected to
\ngrow significantly during the forecast period, as gastric lymphoma is caused by
\nthe formation of abnormal lymphoid tissue in the stomach. In many cases, it
\nforms due to an antigen stimulus by H pylori infection recruits B- and T cells
\nto the gastric mucosa, leading to chronic inflammation. Gastric lymphomas are
\nclassified histologically as marginal zone B-cell lymphomas of MALT-type,
\nDLBCLs, follicular lymphomas, mantle cell lymphomas, Burkitt lymphomas, T-cell
\nlymphomas, and plasmacytomas.<\/p>\n

By End-use Analysis:<\/b><\/p>\n

The hospitals
\nsegment<\/b><\/a> accounted for the largest market share in 2024, as hospital
\ntests and procedures are applied to detect and diagnose gastric cancer. A
\nhealth professional uses a minute camera to see inside the stomach. This
\ntechnique is known as upper endoscopy.\u00a0 The health care team uses the cancer’s
\nstage to understand the prognosis. For gastric cancer, the prognosis for
\nearly-stage cancer is curative. As the stage increases, the chances of a cure
\ndecrease.<\/p>\n

\"A<\/p>\n

On the other hand, the diagnostic
\nlaboratories segment is expected to grow significantly during the forecast
\nperiod as diagnostic laboratories use X-rays to identify gastric cancer.
\nScreening of the cancer I lab is an active area of cancer research. Researchers
\nare studying blood tests and different ways to identify stomach cancer before
\nit causes symptoms. In lab imaging tests applied in diagnosing GC include a
\ncomputerized tomography (CT) scan, magnetic
\nresonance imaging<\/b><\/a> (MRI), bone scan, positron emission tomography (PET)
\nscan, and ultrasound.<\/p>\n

U.S. Gastric Cancer Diagnostics Market
\nKey Regional Analysis:<\/b><\/p>\n

In the United States, the increasing
\nprevalence of digestive system-related cancer and the increasing number of new
\ncases of gastric cancer have been dropping by about 1.5% every year. Due to the
\nincreasing death rate associated with gastric cancer, a prodigious amount of
\nresearch has been conducted on this disease, which increases the market growth.
\nAn enhanced validation and assessment of the novel discovered markers, either
\nby their inclusion in a diagnostic score using digital technology or in
\ncombination with classic diagnostic techniques. In 2024, 2,001,140 novel cancer
\ncases and 611,720 cancer deaths are projected to occur in the United States.<\/p>\n

\u2b25\ufe0eFor Instance, In March 2025, NeoGenomics,
\nInc<\/b><\/a>., a leading provider of oncology testing services, announced the
\nacquisition of Pathline, LLC, a CLIA\/CAP\/NYS-certified laboratory based in New
\nJersey. The acquisition strengthens NeoGenomics\u2019 commercial presence in the
\nNortheast U.S., expanding its service capabilities and accelerating growth in
\nmolecular and hematology-oncology testing by establishing a local presence for
\nthe company in a historically underpenetrated but rapidly growing geographical
\nregion of the country.<\/p>\n

Some of The Prominent Players in The
\nU.S. Gastric Cancer Diagnostics Market Include:<\/b><\/p>\n

\u2022 Exact
\nSciences Corporation<\/b><\/a><\/p>\n

\u2022 Freenome Holdings Inc.<\/p>\n

\u2022 GE
\nHealthcare<\/b><\/a><\/p>\n

\u2022 Guardant Health<\/p>\n

\u2022 Illumina,
\nInc<\/b><\/a><\/p>\n

\u2022 Natera,
\nInc<\/b><\/a><\/p>\n

\u2022 PathAI, Inc<\/p>\n

\u2022 QIAGEN<\/b><\/a><\/p>\n

\u2022 Thermo Fisher Scientific<\/b><\/a><\/p>\n

What is Going Around the Globe?<\/b><\/p>\n

\u2b25\ufe0eIn June 2025, Amgen announced that the Phase 3 FORTITUDE-101
\nclinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6)
\nmet its primary endpoint of overall survival (OS) at a pre-specified interim
\nanalysis. <\/p>\n

\u2b25\ufe0eIn May 2025, Hepion
\nPharmaceuticals, Inc<\/b><\/a>., a clinical stage biopharmaceutical company that
\nhad been developing a treatment for non-alcoholic steatohepatitis,
\nhepatocellular carcinoma, and other chronic liver diseases, announced that it
\nhas entered into a binding letter of intent with New Day Diagnostics LLC to
\nin-license diagnostic tests for celiac disease, respiratory multiplex
\n(Covid\/Influenza A\/B and RSV), helicobacter pylori (H. pylori) and
\nhepatocellular carcinoma (HCC).<\/p>\n

You can place an order or ask any
\nquestions, please feel free to contact at\u00a0<\/b>sales@novaoneadvisor.com<\/b><\/a> \u00a0|
\n+1 804 441 9344<\/b><\/p>\n

Related Report \u2013 <\/b><\/p>\n

\u2b25\ufe0eCancer Diagnostics Market- <\/b>https:\/\/www.precedenceresearch.com\/cancer-diagnostics-market<\/b><\/a>
\n<\/b><\/p>\n

\u2b25\ufe0eNon-Invasive Cancer Diagnostics Market- <\/b>https:\/\/www.precedenceresearch.com\/non-invasive-cancer-diagnostics-market<\/b><\/a>
\n<\/b><\/p>\n

\u2b25\ufe0eBreast Cancer Diagnostics Market- <\/b>https:\/\/www.precedenceresearch.com\/breast-cancer-diagnostics-market<\/b><\/a>
\n<\/b><\/p>\n

\u2b25\ufe0eNext Generation Cancer Diagnostics Market- <\/b>https:\/\/www.precedenceresearch.com\/next-generation-cancer-diagnostics-market<\/b><\/a>
\n<\/b><\/p>\n

\u2b25\ufe0eColorectal Cancer Diagnostics Market- <\/b>https:\/\/www.precedenceresearch.com\/colorectal-cancer-diagnostics-market<\/b><\/a>
\n<\/b><\/p>\n

\u2b25\ufe0eBlood Cancer Diagnostics Market- <\/b>https:\/\/www.precedenceresearch.com\/blood-cancer-diagnostics-market<\/b><\/a>
\n<\/b><\/p>\n

\u2b25\ufe0eProstate Cancer Diagnostics Market- <\/b>https:\/\/www.precedenceresearch.com\/prostate-cancer-diagnostics-market<\/b><\/a>
\n<\/b><\/p>\n

\u2b25\ufe0eLung Cancer Diagnostics Market- <\/b>https:\/\/www.precedenceresearch.com\/lung-cancer-diagnostics-market<\/b><\/a>
\n<\/b><\/p>\n

Segments Covered in the Report<\/b><\/p>\n

This report forecasts revenue growth at
\ncountry levels and provides an analysis of the latest industry trends in each
\nof the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc.
\nhas segmented the U.S. Gastric Cancer Diagnostics Market.<\/p>\n

By Product<\/b><\/p>\n

\u2022 Reagents & Consumables<\/p>\n

\u2022 Instruments<\/p>\n

By Disease Type<\/b><\/p>\n

\u2022 Adenocarcinoma<\/p>\n

\u2022 Gastric lymphoma<\/p>\n

\u2022 Others<\/p>\n

By End-use<\/b><\/p>\n

\u2022 Diagnostic Imaging <\/p>\n

\u2022 Diagnostic Laboratories<\/p>\n

\u2022 Hospitals<\/p>\n

Immediate Delivery Available | Buy This
\nPremium Research <\/b>https:\/\/www.novaoneadvisor.com\/report\/checkout\/9170<\/b><\/a>
\n<\/b><\/p>\n

About-Us<\/b><\/p>\n

Nova One Advisor is a global leader
\nin market intelligence and strategic consulting, committed to delivering deep,
\ndata-driven insights that power innovation and transformation across
\nindustries. With a sharp focus on the evolving landscape of life sciences, we
\nspecialize in navigating the complexities of cell and gene therapy, drug
\ndevelopment, and the oncology market, enabling our clients to lead in some of
\nthe most revolutionary and high-impact areas of healthcare.<\/p>\n

Our expertise spans the entire
\nbiotech and pharmaceutical value chain, empowering startups, global
\nenterprises, investors, and research institutions that are pioneering the next
\ngeneration of therapies in regenerative medicine, oncology, and precision
\nmedicine. <\/p>\n

Web: <\/b>https:\/\/www.novaoneadvisor.com\/<\/b><\/a><\/p>\n

Contact Us<\/b><\/p>\n

USA:<\/b>\u00a0+1 804 441 9344<\/p>\n

APAC:<\/b>\u00a0+61 485 981 310 or +91 87934 22019<\/p>\n

Europe:<\/b>\u00a0+44 7383 092 044<\/p>\n

Email: <\/b>sales@novaoneadvisor.com<\/b><\/a><\/p>\n

Our Trusted Data
\nPartners:<\/b><\/p>\n

Precedence
\nResearch<\/b><\/a> | <\/b>Towards Healthcare<\/b><\/a> |\u00a0Statifacts<\/a> <\/b><\/p>\n

For Latest Update
\nFollow Us: <\/b>LinkedIn<\/b><\/a><\/p><\/p>\n","protected":false},"excerpt":{"rendered":"The U.S. gastric cancer diagnostics market size is expected to be worth around 970.95 million by 2034, increasing…\n","protected":false},"author":3,"featured_media":46661,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[64,135,67,132,68],"class_list":{"0":"post-46660","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-markets","8":"tag-business","9":"tag-markets","10":"tag-united-states","11":"tag-unitedstates","12":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/114813441348115704","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/46660","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=46660"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/46660\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/46661"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=46660"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=46660"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=46660"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}